This alteration associated with a BRAF p.V600E mutation promotes a better prognosis in CRC patients who receive PD-1/PD-L1 inhibitors and the combination of anti-EGFR/BRAF therapy [23]. The gene discussed is BRAF; the disease is colorectal carcinoma.